Human Glioblastoma Stem‐Like Cells are More Sensitive to Allogeneic NK and T Cell‐Mediated Killing Compared with Serum‐Cultured Glioblastoma Cells

• DOI: 10.1111/j.1750-3639.2011.00515.x
• Publication Date: 2011-07-26T14:45:32Z
• Authors: Tony Avril; Elodie Vauleon; Abderrahmane Hamlat; Stéphan Saikali; Amandine Etcheverry; Caroline Delmas; Sylma Diabira; Jean Mosser; Véronique Quillien
• Keywords: cancer stem cells; 0301 basic medicine; [SDV.IMM] Life Sciences [q-bio]/Immunology; Brain Neoplasms; cytotoxic T cells; glioblastoma; [SDV.CAN]Life Sciences [q-bio]/Cancer; NK cells; Culture Media, Serum-Free; 3. Good health; Killer Cells, Natural; 03 medical and health sciences; [SDV.CAN] Life Sciences [q-bio]/Cancer; T-Lymphocyte Subsets; Cell Line, Tumor; Spheroids, Cellular; Neoplastic Stem Cells; [SDV.IMM]Life Sciences [q-bio]/Immunology; Humans; [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]; [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]; cell therapy; Glioblastoma; Cell Line, Transformed

Glioblastoma multiforme (GBM) is the most dramatic primary brain cancer with a very poor prognosis because of inevitable disease recurrence. The median overall survival less than 1 year after diagnosis. Cancer stem cells have recently been disclosed in GBM. GBM stem-like (GSCs) exhibit resistance to radio/chemotherapeutic treatments and are therefore considered play an important role GSCs thus appealing targets for new patients. In this study, we show that cell characteristics resistant lysis mediated by resting natural killer (NK) expression MHC class I molecules. However, killed lectin-activated NK cells. Furthermore, experiments using therapeutic antibody CetuximAb, sensitive antibody-mediated cytotoxicity. We confirm sensitivity GSC cytotoxicity carried out IL2-activated tumor-specific T More importantly, more cell-mediated relatively their corresponding serum-cultured obtained from same initial tumor specimen. Altogether, these results demonstrate immune and, therefore, strongly suggest suitable target immunotherapy